SAN DIEGO, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen
Aselage, chief executive officer, will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday,
January 12, 2017 at 10:30 a.m. PT.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90
days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to
people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring
clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental
glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease,
and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically
begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway.
Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®,
Cholbam® and Chenodal®.
Retrophin.com
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com
